Inhibition of the autocrine IL6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+breast cancers

被引：0
|
作者：
Silva, J.
Rodriguez-Barrueco, R.
Yu, J.
Kalinsky, K.
Maurer, M.
Califano, A.
机构：
[1] Mt Sinai Sch Med, New York, NY USA
[2] Columbia Univ, Nyc, NY USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-PD3-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-03
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers
    Rodriguez-Barrueco, Ruth
    Yu, Jiyang
    Saucedo-Cuevas, Laura P.
    Olivan, Mireia
    Llobet-Navas, David
    Putcha, Preeti
    Castro, Veronica
    Murga-Penas, Eva M.
    Collazo-Lorduy, Ana
    Castillo-Martin, Mireia
    Alvarez, Mariano
    Cordon-Cardo, Carlos
    Kalinsky, Kevin
    Maurer, Matthew
    Califano, Andrea
    Silva, Jose M.
    GENES & DEVELOPMENT, 2015, 29 (15) : 1631 - 1648
  • [2] The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+breast cancers
    Fusco, N.
    Sajjadi, E.
    Venetis, K.
    Invernizzi, M.
    Gambini, D.
    Blundo, C.
    Runza, L.
    Ferrero, S.
    Rocco, E. Guerini
    ANNALS OF ONCOLOGY, 2021, 32 : S25 - S25
  • [3] Combined analysis of PTEN and routinely assessed biomarkers reveals new high-risk subgroups of HR- or HER2+breast cancers
    Fusco, Nicola
    Sajjadi, Elham
    Venetis, Konstantinos
    Invernizzi, Marco
    Gambini, Donatella
    Runza, Letterio
    Ferrero, Stefano
    Guerini-Rocco, Elena
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Treating trastuzumab-resistant HER2+breast cancers with a HER3-targeted nanoparticle
    Sims, Jessica D.
    Tagualm, Michael
    Hanson, Chris
    Cui, Xiaogang
    Medina-Kauwe, Lail K.
    CANCER RESEARCH, 2013, 73
  • [5] DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+breast cancer
    Momeny, Majid
    Tienhaara, Mari
    Sharma, Mukund
    Chakroborty, Deepankar
    Varjus, Roosa
    Takala, Iina
    Merisaari, Joni
    Padzik, Artur
    Vogt, Andreas
    Paatero, Ilkka
    Elenius, Klaus
    Laajala, Teemu D.
    Kurppa, Kari J.
    Westermarck, Jukka
    EMBO MOLECULAR MEDICINE, 2024, 16 (07) : 1603 - 1629
  • [6] Novel Herceptin-Based IHC Test Detects HER2+Breast Cancers Correlating to Responses to HER2-Targeted Therapy
    He, Jian
    Zhang, Zhiqing
    Chen, Shuo
    Motiee, Angelina
    Zhang, Yonghua
    Zhao, Songqing
    Wang, Jianfu
    Albarracin, Constance T.
    Abraham, Susan
    Wu, Yim
    LABORATORY INVESTIGATION, 2017, 97 : 529A - 529A
  • [7] Novel Herceptin-Based IHC Test Detects HER2+Breast Cancers Correlating to Responses to HER2-Targeted Therapy
    He, Jian
    Zhang, Zhiqing
    Chen, Shuo
    Motiee, Angelina
    Zhang, Yonghua
    Zhao, Songqing
    Wang, Jianfu
    Albarracin, Constance T.
    Abraham, Susan
    Wu, Yun
    MODERN PATHOLOGY, 2017, 30 : 529A - 529A
  • [8] The role of IL-6/JAK2/STAT3 signaling pathway in cancers
    Huang, Bei
    Lang, Xiaoling
    Li, Xihong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+breast cancer models
    Xia, Wenle
    Petricoin, Emanual F., III
    Zhao, Sumin
    Liu, Leihua
    Osada, Takuya
    Cheng, Qing
    Wulfkuhle, Julia D.
    Gwin, William R.
    Yang, Xiaoyi
    Gallagher, Rosa I.
    Bacus, Sarah
    Lyerly, H. Kim
    Spector, Neil L.
    BREAST CANCER RESEARCH, 2013, 15 (05)
  • [10] TTK promotes HER2+breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis
    Zhang, Shaolin
    Ding, Hua
    Deng, Yongfen
    Ren, Yu
    Zhou, Fulin
    Zhang, Qian
    Liu, Shu
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (12)
12345